Renowned Prostate Cancer Experts Present Latest Findings At UCSF Cancer Center Symposium

May 21, 1999

The latest discoveries related to prostate cancer research, diagnosis and treatment will be presented by several of the nation's leading cancer experts during an all-day symposium at the University of California, San Francisco.


Researchers will present the most recent information regarding cellular interactions in prostate cancer, new gene discoveries and techniques for measuring patient outcomes. In addition, new results of clinical trials of experimental agents for the treatment of prostate cancer--including immunotherapies and alternative therapies--will be presented.

Speakers at the UCSF Cancer Center symposium include Peter Carroll, M.D., chair, department of urology, UC San Francisco; Alice Whittemore, Ph.D., department of epidemiolgy and health research and policy, Stanford University; and Owen Witte, M.D., department of microbiology and molecular genetics, UC Los Angeles.

Prostate cancer--which will claim an estimated 37,000 lives this year--is a significant health care problem in the U.S. due to high incidence and mortality, costs associated with detection and treatment, and lack of consensus regarding the best form of treatment for each stage of the disease.

In addition, the causes of prostate cancer are multiple, incorporating familial (genetic) elements, as well as probable racial, cultural, and environmental factors, such as diet.
-end-
UCSF CANCER CENTER SYMPOSIUM
TUESDAY, MAY 25, 1999
UCSF CAMPUS, COLE HALL
9:00 AM-5:00 PM

University of California - San Francisco

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.
Can't connect to localhost. Errorcode: 1203